Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIVE BEYOND: Doravirine in NNRTI-Resistant HIV
NCT02629822Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Jan 2016; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02629822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629822.